Williston (OTCMKTS:WHCA) versus Inozyme Pharma (NASDAQ:INZY) Critical Contrast

Williston (OTCMKTS:WHCA) and Inozyme Pharma (NASDAQ:INZY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Williston and Inozyme Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Williston	0	0	0	0	0.00
Inozyme Pharma	0	0	8	0	3.00

Inozyme Pharma has a consensus price target of $17.00, suggesting a potential upside of 518.18%. Given Inozyme Pharma’s stronger consensus rating and higher probable upside, analysts plainly believe Inozyme Pharma is more favorable than Williston.

Profitability

This table compares Williston and Inozyme Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Williston	N/A	N/A	N/A
Inozyme Pharma	N/A	-88.42%	-57.02%

Earnings & Valuation

This table compares Williston and Inozyme Pharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Williston	N/A	N/A	N/A	N/A	N/A
Inozyme Pharma	N/A	N/A	-$71.17 million	($1.56)	-1.76

Insider & Institutional Ownership

88.3% of Inozyme Pharma shares are held by institutional investors. 11.2% of Inozyme Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Williston has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.

Summary

Inozyme Pharma beats Williston on 5 of the 8 factors compared between the two stocks.

About Williston

Williston Holding Company, Inc. owns and operates restaurants. The company was incorporated in 2012 and is based in Eden Prairie, Minnesota.

About Inozyme Pharma

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.